Urgent Recall: Diabetes Supplement CuraLin Poses Seizure and Coma Risks Due to Incorrect Usage
The Health Sciences Authority (HSA) has issued a recall for the diabetes supplement CuraLin after detecting a significant risk of seizures and coma if taken incorrectly. Tests conducted on the capsules revealed that they contained two prescription-only medicines, which can have serious health consequences if not used properly. This recall highlights the importance of adhering to proper dosage and usage guidelines for health supplements, particularly those that may interact with other medications or have adverse effects. Consumers are advised to exercise caution and consult their healthcare providers before taking any supplements, especially those with pre-existing medical conditions. The recall of CuraLin serves as a reminder of the potential risks associated with unregulated health products and the need for stringent quality control measures. For more information on the recall and safe usage of health supplements, visit reputable online sources such as straitstimes.com. Key terms associated with this recall include diabetes management, health supplement risks, and prescription medication interactions.
